Search Follow us
Refine By

Type of Publication

codon

1 - 3 of 3
Sort by: popularity | newest
Page  of 1
CO.DON

Building roll-out momentum in Europe

QuickView | Pharmaceuticals & healthcare | 19 Nov 2018

CO.DON is a manufacturer of autologous cell therapies for the treatment ofcartilage defects. The main product, Spherox, is based on the corespheroid technology and can repair cartilage defects of the knee via aminimally invasive procedure. After accumulating supportive data from thePhase III (ongoing) and the Phase II ‘co.dis' (successfully completed thisyear) trials, CO.DON obtained marketing authorisation from the EMA inJuly 2017 and is now rolling out Spherox in several European markets.This has been slower than initially expected due to the transition periodfrom the older product and reimbursement issues, but the companyexpects progress by the end of Q318 and guides break-even by 2021.

CO.DON

Green light for Spherox from the EMA

QuickView | Pharmaceuticals & healthcare | 15 Nov 2017

CO.DON is a leading manufacturer of autologous cell therapies for the treatment of cartilage defects. The company's main product, Spherox, is based on the core spheroid technology and can repair cartilage defects of the knee of up to 10cm2 in a minimally invasive procedure. The Phase III clinical trial allowed CO.DON to obtain marketing authorisation from the European Medicine Agency (EMA) in July 2017, which opened access to all European markets. The company is preparing for the roll-out of Spherox and has already received a green light from the UK's National Institute for Health and Care Excellence (NICE).

CO.DON

Leaders in cartilage repair

QuickView | Pharmaceuticals & healthcare | 09 Nov 2015

co.don is a leading producer of autologous cell and tissue transplants for the treatment of cartilage defects: chondrosphere is used for articular cartilage defects and chondrotransplant DISC is used for spinal disc defects. The products are successfully marketed in Germany (revenues of€4.5m in FY14, double-digit y-o-y growth). Two clinical trials of chondrosphere are underway (a Phase II and Phase III) to obtain EMA authorisation for EU-wide distribution, targeted for 2017.